A pilot proof of concept study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)

Brief description of study

The purpose of this research is to study the effects of administering an oral short chain fatty acid (SCFA) dietary supplement along with methotrexate as first line treatment in new onset rheumatoid arthritis (RA) patients. Short chain fatty acids (SCFAs) are gut bacterial fermentation byproducts that are naturally found at varying concentrations in the gut and have been shown to increase host regulatory immune responses and induce changes in the gut microbiota in various animal models of inflammatory disease. SCFAs are not an FDA approved treatment for RA or for any other condition but are sold over the counter as nutritional supplements.

Clinical Study Identifier: s20-02068
ClinicalTrials.gov Identifier: NCT05152615
Principal Investigator: Jose U Scher.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.